NKTR is down -8.64% in regular trading, falling to about $55.32 from its prior close of $60.55. The selloff was driven by jury deliberations in Nektar's breach-of-contract lawsuit against Eli Lilly over its Rezpeg drug.

KOD shares climbed roughly +155.8% over 30 days, from about $37.06 on September 1, 2026 to $94.80 on September 30, 2026. The surge followed positive Phase 3 DAYBREAK trial results announced September 28, 2026, showing Zenkuda and tabirafusp-ted met their primary endpoints in wet age-related macular degeneration (wet AMD).

The $1.00 figure is a single published research target from First Berlin Equity Research, not a multi-analyst consensus; NWBO has essentially one active coverage note. With the stock near $0.17, reaching $1.00 would require a gain of roughly 490%, a very large move by any standard.

Capricor Therapeutics (CAPR) is a clinical-stage biotech whose near-term outlook is dominated by the U.S. FDA review of its lead candidate, Deramiocel, for Duchenne muscular dystrophy (DMD). Over roughly the past 30 days, the stock has traded in a range without a sustained double-digit move, reflecting a balance between recent analyst upgrades and lingering regulatory and legal uncertainty.

CAPR is up +14.12% intraday to $9.78, versus a prior-session close of $8.57, extending a rally that began in Tuesday's after-hours session. Primary catalyst: new 24-month HOPE-3 open-label extension data for deramiocel in Duchenne muscular dystrophy, presented at the World Muscle Society congress, showing durable slowing of upper-limb decline.

MRNA is trading down -5.25% to about $192.78 in the regular session, extending a decline that began premarket after Citi downgraded the stock to Sell from Neutral. Primary catalyst: Citi's Geoff Meacham called the valuation "unjustifiable" after a 222% rally since the INTerpath-001 cancer-vaccine data, even while raising the price target to $80 from $60 — still roughly 60% below the prior close.

Iovance Biotherapeutics (IOVA) shares rose roughly 77% over the past 30 days, climbing from about $8.17 to $14.45 per share. The rally was powered by a raised full-year 2026 revenue outlook, driven by strong demand for Amtagvi and Proleukin.

Both are speculative, small-cap biotech/pharma names trading on the Nasdaq with sub-$1-to-low-single-digit share prices and elevated volatility. FLNA is a clinical-stage developer of CNS (central nervous system) therapies that has faced an FDA clinical hold and a Nasdaq listing-compliance notice.

EVGN is trading up +10.42% intraday (to roughly $0.42), rebounding during the regular session from a prior close of $0.38. The gain follows yesterday's -8.59% post-earnings selloff after Q2 2026 results reported EPS of -$0.63 and revenue down 76.4% year-over-year to $670K.

JAGX is down -12.96% to $5.24 in regular trading, extending a slide from the prior session's $6.02 close. The drop follows an earlier squeeze that briefly sent shares up as much as +2,261% intraday on crofelemer pipeline and FDA fee-waiver news.

IOVA is up +36.67% in the regular session, surging from a prior close of $10.99 to about $15.02 after gapping higher in premarket trading. Primary catalyst: the company raised its full-year 2026 revenue guidance to $410–$420 million, up from $350–$370 million.

NNVC fell -11.33% during regular trading, sliding from a $1.50 prior close to about $1.33. The decline followed the filing of its annual report, with EPS of -$0.10 missing the -$0.09 estimate.

ACET (Adicet Bio) is a clinical-stage cell therapy developer that recently reported positive Phase 1 lupus data, yet its shares remain highly volatile. VIR (Vir Biotechnology) swung to a quarterly profit on a major collaboration payment and carries a near-term pivotal hepatitis delta readout.

KPTI fell roughly -21% during regular trading, sliding from a $1.62 prior close to about $1.28. The decline extends a prolonged downtrend rather than a single new headline, reflecting acute liquidity concerns.

AZTR fell -23.53% during regular trading, dropping to about $0.13 from a prior close of $0.17. The catalyst was Azitra's disclosure of an at-the-market (ATM) sales agreement with A.G.P./Alliance Global Partners to issue up to roughly $3.5 million in new common stock.

ONCO fell -27.93% to $0.80 during regular market hours, down from the prior session's $1.11 close. The decline occurred intraday, reversing most of the prior week's sharp speculative gains.

SLXN gained +25.5% to about $0.31 during Monday's regular session, building on a +66.6% pre-market surge from Friday's $0.2484 close. The catalyst was positive preclinical data for lead RNAi candidate SIL204, showing native serum lipoproteins drive cellular uptake and dose-dependent KRAS knockdown in cancer cells.

CDT Equity shares fell about -21% to roughly $1.50 in regular-session trading, their first day on a split-adjusted basis. The decline follows a 1-for-25 reverse stock split (effective Sept. 28 after the close), executed to regain Nasdaq minimum bid-price compliance.

NAUT is trading up +33.33% to roughly $1.48, versus a prior session close of $1.11, during regular market hours. Primary catalyst: Roth/MKM (Roth Capital) initiated coverage with a Buy rating and a $3.50 price target, implying substantial upside.

LeonaBio (LONA) shares are up +25.09% intraday during regular trading, rising to about $3.59 from Monday's close of $2.87. The jump is a sharp rebound after a multi-day rout that cut the stock roughly 55% from ~$6.05 on Sept. 22.